Abstract:Embryonic stem cell pathways such as hedgehog and Wnt pathways are central to the tumorigenic properties of cancer stem cells (CSC). Since CSCs are characterized by their ability to self-renew, form differentiated progeny, and develop resistance to anticancer therapies, targeting the Wnt and hedgehog signaling pathways has been an important strategy for cancer treatment. Although molecules targeting either Wnt or hedgehog are common, to the best of our knowledge, those targeting both pathways have not been documented. Here we report a small molecule (compound 1) that inhibits both Wnt (IC50 = 0.5 nM) and hedgehog (IC50 = 71 nM) pathways based on reporter gene assays. We further identified that the molecular target of 1 for Wnt pathway inhibition was porcupine (a member of the membrane-bound O-acyltransferase family of proteins), a post-translational modification node in Wnt signaling; while the target of 1 mitigating hedgehog pathway was Smoothened, a key G protein coupled receptor (GPCR) mediating hedgehog signal transduction. Preliminary analysis of structure-activity-relationship identified key functional elements for hedgehog/Wnt inhibition. In in vivo studies, compound 1 demonstrated good oral exposure and bioavailability while eliciting no overt toxicity in mice. An important consideration in cancer treatment is the potential therapeutic escape through compensatory activation of an interconnected pathway when only one signaling pathway is inhibited. Toward this end, compound 1 may not only lead to the development of new therapeutics for Wnt and hedgehog related cancers, but may also help to develop potential cancer treatment which needs to target Wnt and hedgehog signaling simultaneously.

Current approaches and strategies to identify Hedgehog signaling pathway inhibitors for cancer therapy

Current Status of Hedgehog Signaling Inhibitors

Strategies to target the Hedgehog signaling pathway for cancer therapy

Progress in research of novel anticancer drugs targeting Hedgehog signaling pathway

Hedgehog Inhibitors: a Patent Review (2013 – Present)

Hedgehog Signaling: from Basic Biology to Cancer Therapy

Progress in Research on Small Molecular Inhibitors of Hedgehog Signal Pathway

Hedgehog Pathway Inhibitors as Targeted Cancer Therapy and Strategies to Overcome Drug Resistance

Hedgehog Signaling in Tissue Homeostasis, Cancers, and Targeted Therapies.

Hedgehog Signaling Pathway and Autophagy in Cancer

Clinical Research Progress of Hedgehog Signaling Path ways

Investigations on Inhibitors of Hedgehog Signal Pathway: A Quantitative Structure-Activity Relationship Study

Discovery and Characterization of a Potent Wnt and Hedgehog Signaling Pathways Dual Inhibitor.

Molecular pathways: the role of primary cilia in cancer progression and therapeutics with a focus on Hedgehog signaling

New insight into hedgehog signaling in hematological malignancies.

Hedgehog Pathway Inhibitors against Tumor Microenvironment

Beyond cyclopamine: Targeting Hedgehog signaling for cancer intervention

Discovery of Novel 4-(2-pyrimidinylamino)benzamide Derivatives As Highly Potent and Orally Available Hedgehog Signaling Pathway Inhibitors

Blockade of hedgehog signaling pathway as a therapeutic strategy for pancreatic cancer

A Novel Hedgehog Inhibitor for the Treatment of Hematological Malignancies

The Discovery of Novel N-(2-pyrimidinylamino) Benzamide Derivatives As Potent Hedgehog Signaling Pathway Inhibitors